This clinical trial is focused on studying the effectiveness and safety of vaccines designed to protect against the influenza virus, commonly known as the flu. The study involves two types of vaccines: the Adjuvanted Trivalent Influenza Vaccine (aTIV) and the FLUARIX (Influenza Vaccine). Both vaccines are given as a shot in the muscle and are designed to protect against different strains of the flu virus, including the Influenza Virus B/Austria/1359417/2021-like strain, A/Victoria/4897/2022 (H1N1)pdm09-like strain, and Influenza Virus A/Thailand/8/2022 (H3N2) IVR-237-like strain.
The purpose of this study is to compare how well the MF59-adjuvanted influenza vaccine works in preventing the flu compared to a non-adjuvanted vaccine in adults aged 65 and older. An adjuvant is a substance added to a vaccine to help boost the body’s immune response to the vaccine. Participants in the study will receive one of the two vaccines and will be monitored to see if they develop the flu, confirmed by a test called RT-PCR, which detects the presence of the virus in the body.
The study will take place over the course of the flu season, starting 14 days after vaccination. Participants will be observed for any side effects and the occurrence of flu symptoms. The study aims to provide valuable information on the safety and effectiveness of these vaccines in older adults, helping to improve flu prevention strategies for this age group.



Belgium
Bulgaria
Czechia
Finland
Italy
Lithuania
Poland
Romania
Spain
The Netherlands